Sirtuins and multiple sclerosis
Multiple sclerosis (MS) is a challenging and disabling condition especially in the secondary progressive (SP) phase of this disease. Available treatments cannot improve or stop disease progression at this stage, and there is an urgent need to focus on effective therapies and molecular pathways involved in SPMS.
Given the significant impact of neurodegeneration, autoimmunity and metabolic alterations in MS, focusing on molecules that target these different pathways could help find new treatments. Sirtuins (SIRTs) are NAD+-dependent epigenetic and metabolic regulators that play critical roles in central nervous system physiology, the immune system and metabolism. Based on these facts, SIRTs are crucial candidates for therapeutic targets in multiple sclerosis and collecting MS disease-related information for each SIRT individually is noteworthy and highlights the lack of investigation in each part.
Sirtuins and multiple sclerosis, scientific studies
In this study, the roles of several sirtuins as key regulators in neurodegeneration, autoimmunity and metabolic pathways were summarised. The rationale behind the selection of SIRTs as therapeutic targets in MS disease was elucidated by collecting research showing the alteration of these proteins in human samples of MS patients and in animal models of MS, and also the improvement of animals after direct treatment with SIRTs.
Sirtuins and multiple sclerosis, a preventive strategy to ensure longevity and well-being without chronic and autoimmune diseases by mimicking calorie restriction with natural polyphenol-based foods and supplements.
Editorial Staff SIRT500 – The Fountain of Youth